Nabriva Therapeutics AG (NASDAQ:NBRV) – Research analysts at Leerink Swann issued their Q3 2016 earnings per share estimates for shares of Nabriva Therapeutics AG in a research note issued to investors on Thursday. Leerink Swann analyst P. Matteis anticipates that the brokerage will earn ($0.65) per share for the quarter. Leerink Swann has a “Outperform” rating and a $14.00 price target on the stock. Leerink Swann also issued estimates for Nabriva Therapeutics AG’s Q4 2016 earnings at ($0.70) EPS, FY2016 earnings at ($2.55) EPS, FY2017 earnings at ($1.87) EPS and FY2018 earnings at ($2.40) EPS.
Nabriva Therapeutics AG (NASDAQ:NBRV) last posted its quarterly earnings results on Tuesday, August 9th. The company reported ($0.50) EPS for the quarter, beating the Zacks’ consensus estimate of ($6.25) by $5.75.
A number of other equities analysts have also recently commented on NBRV. Zacks Investment Research raised shares of Nabriva Therapeutics AG from a “hold” rating to a “buy” rating and set a $8.50 price target for the company in a research note on Friday, August 12th. HC Wainwright started coverage on shares of Nabriva Therapeutics AG in a research report on Thursday, September 8th. They issued a “buy” rating and a $16.00 price objective for the company. Finally, Wedbush reissued an “outperform” rating and issued a $17.00 price objective on shares of Nabriva Therapeutics AG in a research report on Tuesday, August 9th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $15.18.
Shares of Nabriva Therapeutics AG (NASDAQ:NBRV) opened at 6.01 on Monday. The stock’s market cap is $127.69 million. The stock’s 50 day moving average is $6.99 and its 200-day moving average is $7.68. Nabriva Therapeutics AG has a 12-month low of $4.99 and a 12-month high of $10.69.
Several large investors have recently bought and sold shares of the stock. Vivo Capital LLC acquired a new stake in Nabriva Therapeutics AG during the first quarter valued at approximately $28,239,000. Opaleye Management Inc. raised its stake in Nabriva Therapeutics AG by 24.5% in the first quarter. Opaleye Management Inc. now owns 273,800 shares of the company’s stock valued at $2,453,000 after buying an additional 53,800 shares in the last quarter. Finally, Jackson Park Capital LLC acquired a new stake in Nabriva Therapeutics AG during the second quarter valued at approximately $195,000. Institutional investors and hedge funds own 63.05% of the company’s stock.
About Nabriva Therapeutics AG